CS
XENE icon

Candriam SCA’s Xenon Pharmaceuticals XENE Stock Holding History

Candriam SCA’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.9M Sell
462,768
-13,726
-3% -$762K 0.13% 160
2026
Q1 		$27.7M Buy
476,494
+59,092
+14% +$2.72M 0.14% 152
2025
Q4 		$18.7M Buy
417,402
+20,766
+5% +$872K 0.09% 198
2025
Q3 		$15.9M Hold
396,636
– – 0.08% 208
2025
Q2 		$12.4M Sell
396,636
-58,014
-13% -$1.89M 0.07% 216
2025
Q1 		$15.3M Sell
454,650
-37,531
-8% -$1.43M 0.1% 193
2024
Q4 		$19.3M Buy
492,181
+28,320
+6% +$1.17M 0.11% 169
2024
Q3 		$18.3M Sell
463,861
-57,975
-11% -$2.34M 0.1% 192
2024
Q2 		$20.3M Sell
521,836
-39,048
-7% -$1.56M 0.12% 166
2024
Q1 		$24.1M Buy
560,884
+30,000
+6% +$1.38M 0.15% 143
2023
Q4 		$24.5M Sell
530,884
-39,000
-7% -$1.38M 0.17% 132
2023
Q3 		$19.5M Sell
569,884
-136,000
-19% -$5.09M 0.14% 147
2023
Q2 		$27.2M Sell
705,884
-13,322
-2% -$530K 0.2% 131
2023
Q1 		$23.7M Sell
719,206
-16,678
-2% -$616K 0.16% 143
2022
Q4 		$29M Sell
735,884
-25,000
-3% -$910K 0.2% 123
2022
Q3 		$27.5M Sell
760,884
-102,256
-12% -$3.68M 0.19% 118
2022
Q2 		$26.3M Buy
863,140
+258,886
+43% +$7.83M 0.22% 108
2022
Q1 		$18.5M Buy
604,254
+73,743
+14% +$2.21M 0.13% 176
2021
Q4 		$16.6M Sell
530,511
-185,211
-26% -$5.53M 0.11% 197
2021
Q3 		$10.9M Hold
715,722
– – 0.07% 260
2021
Q2 		$13.3M Buy
+715,722
New +$13.2M 0.09% 244

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Candriam SCA's XENE Position: Q2 2026 in Review

Candriam SCA reduced its Xenon Pharmaceuticals (XENE) stake by 2.9% in Q2 2026, selling an estimated $762K and leaving 462,768 shares worth $27.9M. The position accounts for 0.13% of the portfolio, ranked #160.

Candriam SCA first reported a position in XENE in Q2 2021 and has held it in 21 quarters since. The position peaked at $29M in Q4 2022. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Candriam SCA held 462,768 shares of Xenon Pharmaceuticals worth $27.9M as of Q2 2026.
  • Candriam SCA sold 13,726 Xenon Pharmaceuticals shares in Q2 2026, an estimated $762K.
  • Xenon Pharmaceuticals made up 0.13% of Candriam SCA's portfolio in Q2 2026, its #160 holding.
  • Candriam SCA first reported a position in Xenon Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • Candriam SCA's Xenon Pharmaceuticals position peaked at $29M in Q4 2022.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.